Oncology Learning Network· @OncLearnNetwork · X·· 22 小时前评分70
正文 · 机器翻译
如#ESMO2026上所展示的，围手术期#durvalumab联合新辅助 enfortumab vedotin显著改善了不适合或拒绝接受基于顺铂治疗的肌层浸润性膀胱癌患者的生存。
了解更多：https://www.hmpgloballearningnetwork.com/site/onc/news/volga-trial-demonstrates-significant-survival-benefit-durvalumab-plus-enfortumab
43 浏览 · 0 赞 · 1 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：Oncology Learning Network · x.com